1787-17-3

Upstream product

• 589-10-6 phenoxyethyl bromide 
• 105-53-3 diethyl malonate 
• 43224-81-3 2-phenoxyethanol tosylate 
• 122-99-6 2-Phenoxyethanol 
• 139-02-6 sodium phenoxide 
• 108-95-2 phenol 
• 1559-02-0 diethyl cyclopropane-1,1-dicarboxylate 
• 622-86-6 2-chloroethoxybenzene 

Downstream Products

• 854834-11-0 ethyl-(2-phenoxy-ethyl)-malonic acid diethyl ester 
• 6303-58-8 4-phenyloxybutanoic acid 
• 81580-47-4 4-(2-Phenoxy-ethyl)-isoxazolidine-3,5-dione 
• 1558-90-3 2-phenoxyethylmalonic acid ethyl ester 
• 133-13-1 ethyl diethyl malonate 
• 108-93-0 cyclohexanol 
• 103487-19-0 2-(2-Phenoxyethyl)propane-1,3-diol 
• 74884-32-5 (2-phenoxy-ethyl)-malonic acid 
• 861355-79-5 benzyl-(2-phenoxy-ethyl)-malonyl chloride 
• 871886-94-1 benzyl-(2-phenoxy-ethyl)-malonic acid 
• 2364-59-2 γ-phenoxybutyric acid ethyl ester 
• 95434-98-3 4-(2-phenoxy-ethyl)-1,2-diphenyl-pyrazolidine-3,5-dione 

Relevant academic research and scientific papers

beta -thiopropionyl-aminoacid derivatives and their use as beta -lactamase inhibitors

PCT No. PCT/EP97/00516 Sec. 371 Date Jan. 13, 1999 Sec. 102(e) Date Jan. 13, 1999 PCT Filed Feb. 3, 1997 PCT Pub. No. WO97/30027 PCT Pub. Date Aug. 21, 1997A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a beta -lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R1 is hydrogen, (C1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C1-6)alkylcarbonyloxy, (C1-6)alkoxycarbonyl, formyl or (C1-6)alkylcarbonyl group, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C2-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, aryl, aryl(C1-6)alkyl, heterocyclyl or heterocyclyl(C1-6)alkyl; R2 is hydrogen, (C1-6)alkyl or aryl(C1-6)alkyl; R3 is hydrogen, (C1-6)alkyl optionally substituted by up to three halogen atoms, (C3-7)cycloalkyl, fused aryl(C3-7)cycloalkyl, (C3-7)cycloalkyl(C2-6)alkyl, (C2-6)alkenyl, (C2-6)alkynyl, aryl, aryl-(CHR10)m-X-(CHR11)n, heterocyclyl or heterocyclyl-(CHR10)m-X-(CHR11)n, where m is 0 to 3, n is 1 to 3, each R10 and R11 is independently hydrogen or (C1-4)alkyl and X is O, S(O)x where x is 0-2, or a bond; R4 is hydrogen, or an in vivo hydrolysable acyl group; and R5 and R6 are independently hydrogen and (C1-6)alkyl or together represent (CH2)p where p is 2 to 5. Some compounds are claimed per se.

Structure-activity studies of 3-benzoylpropionic acid derivatives suppressing adjuvant arthritis

3-Benzoylpropionic acid derivatives possess an immunomodulative activity and suppress adjuvant arthritis. To understand how substituents affect the biological activity, the quantitative structure-activity relationships of 30 compounds were analyzed by the adaptive least-squares method. For the suppressing activity in rats, the electronic effects and the structural feature of the substituent on benzene ring were suggested to be important. To reinforce and confirm the correlation, 4 additional compounds of phenoxybutyric acid derivatives were synthesized and tested with the rat adjuvant-induced arthritis. These compounds were found to have potent suppressing activity.